Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the DESTINY-Gastric01 trial (NCT03329690) investigating IHC 1-positive (IHC1+) and IHC 2-positive (IHC2+)/ISH-negative (ISH-) patients with HER2-expressing gastric cancer. Antibody-drug conjugate (ADC) trastuzumab derutexcan (T-DXd) was administered in patients, however, to enhance activity, T-DXd will be investigated in combination with capecitabine, nivolumab and oxaliplatin, in an upcoming Phase Ib trial. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть